Dose-comparison study on biapenem in the treatment of chronic bronchitis.
|
Accession number;00A0221181
|
| Title;Dose-comparison study on biapenem in the treatment of chronic bronchitis. |
| Author;
MATSUMOTO FUMIO
(Kanagawa Prefect. Nurses Sch.)
WATANABE AKIRA
(Res. Inst. Tuberculosis and Cancer, Tohoku Univ.)
WADA KOICHI
(National Sanatorium Nishi-Niigata-Chuo Byoin, JPN)
AOKI NOBUKI
(Shinrakuen Byoin)
HOSHINO SHIGEYUKI
(Niigataken Koseiren Cent. Gen. Hosp.)
HARA KOHEI
(Nagasaki Univ., Sch. of Med.)
KONO SHIGERU
(Nagasaki Univ., Sch. of Med.)
NAKASHIMA MITSUYOSHI
(Hamamatsu Univ. Sch. of Med.)
YAMAGUCHI KEIZO
(Toho Univ., Sch. of Med.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.1;PAGE.34-44(2000)
|
| Figure&Table&Reference;FIG.2, TBL.12, REF.10 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In order to reconfirm the optimal dose and search for the clinical benefits of biapenem(BIPM), a parenteral carbapenem antibiotic, in the treatment of acute exacerbation of chronic bronchitis, a randomized, three-group comparative study against imipenem/cilastatin(IPM/CS) as a comparator was performed by using a telephone registration method, and the following results were obtained. BIPM at 300 (group L) or 600 (group H)mg/day in two-divided doses and IPM/CS at 1,000mg/1,000mg/day (group C) in two-divided doses were systemically administered. The duration of treatment was within 14 days. The number of patients evaluated for clinical efficacy out of the total 35 patients registered was 32 cases (L group 10 cases, H group 10 cases, C group 12 cases). 1) Clinical effects: The efficacy rates were 100% (10/10), 90.0% (9/10), and 91.7% (11/12) in group L, H, and C, respectively. For the evaluation of early onset after 3 days of treatment, the efficacy rates were 60.0% (6/10), 90.0% (9/10), and 58.3% (7/12) in group L, H, and C, respectively. 2) Bacteriological effects: The bacterial eradication rates were 100% (6/6), 100% (3/3), and 100% (9/9) in groups L, H, and C, respectively. 3) Side effects were observed at a rate of 8.3% (1/12) in group C. The severity of the drug fever/drug eruption was moderate. No side effects were observed in group L and H. 4) Abnormal laboratory findings were observed at a rate of 20% (2/10) in group L, 33.3% (4/12) in group H, and 20% (2/10) in group C. These abnormal findings were mild. 5) Usefulness: The usefulness rates were 100% (10/10), 90% (9/10), and 83.3% (10/12) in groups L, H, and C, respectively. There were no statistical differences in every evaluation among the 3 groups. The rate of efficacy on day 3 that reflects the early response of the drug treatment is 600mg a day and the highest efficacy rate.... (author abst.) |
|
|
|
Related Articles;
|
|
